Study Site 381 — Chicago, Illinois

Study Site 381 is a clinical research site located in Chicago, Illinois, United States.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Study Site 381 has participated in 1 clinical trials.

Therapeutic areas: Pruritus, Atopic Dermatitis.

Sponsors: Vyne Therapeutics Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Chicago

Browse all research sites in Illinois · View every site in Chicago

• The University of Chicago Medicine Duchossois Center for Advanced Medicine
• Jeffrey Kramer, MDSC at Mercy Hospital
• University Consultants in Allergry and Immunology
• Rush University Med Ctr
• University of Illinois Medical Center in Chicago
• University of Chicago Medical Center (UCMC) Center for Advanced Medicine (CAM)
• Rush University Medical Center-Orthopedic Spine
• Northestern University
• University of Chicao
• Rush University Medical Center - Department Of Cardiology
• Northwestern University Diagnostic Testing Center
• University of Illinois Chicago

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Study Site 381?

Study Site 381 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Study Site 381 conducted?

Study Site 381 has 1 clinical trials on record. Their work covers Pruritus, Atopic Dermatitis.

Is Study Site 381 accredited by Crixeo Clinical Trials?

Study Site 381 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Study Site 381?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.